What is already known about this subject:
- Drug induced liver injury (DILI) is a major concern in the treatment
of tuberculosis (TB).
- There are new biomarkers for DILI (microRNA-122 and cytokeratin-18)
which have the potential to add value because of enhanced
specificity/sensitivity compared to current tests.
- These mechanistically informative DILI biomarkers have qualifying data
from large USA and European studies. However, these markers have not
been tested in Africa. Given the global burden of TB our aim was to
explore biomarker utility in this global context of use.